Compare Marsh & McLennan Companies, Inc. (MRSH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Marsh & McLennan Companies, Inc. trades at $176.89 (market cap $86.15B), while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: Marsh & McLennan Companies, Inc. pays a 2.19% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Marsh & McLennan Companies, Inc. nearer its low. Which is the better fit depends on your goals.
| MRSH | XBI | |
|---|---|---|
Market Cap | $86.15B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $207.02 | $169.55 |
52-Week Low | $157.32 | $93.43 |
Enterprise Value | $106.83B | — |
Dividend Yield | 2.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $180.52, down 2.81% on the day, with a bullish technical signal despite recent weakness. The stock shows strong fundamentals, including consistent earnings beats, a 14.24% net income margin, and robust cash flow. Recent news highlights growth in healthcare consulting and cyber risk services, supporting revenue expansion.
Outlook remains positive with a consensus price target of $208.63, offering 15% upside. Risks include economic sensitivity and debt levels, but analyst sentiment leans bullish with 30% buy ratings. The stock presents a growth opportunity in professional services, backed by solid financials and strategic initiatives.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
